On February 3, 2023, the U.S. Food and Drug Administration approved sacituzumab govitecan-hziy for women 18 years or older with HR+/HER2-Metastatic Breast Cancer refractory to or relapsed after at least 2, and
Dr. Rubina Suwal of the Binaytara Foundation Cancer Center performs successful oral cancer surgery for patient in local community
More